DEPOSIT AGREEMENTDeposit Agreement • May 23rd, 2018 • Realm Therapeutics PLC • Pharmaceutical preparations • New York
DEPOSIT AGREEMENT, dated as of ___________, 2018, by and among (i) Realm Therapeutics plc, a public limited company incorporated under the laws of England and Wales, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
TECHNOLOGY TRANSFER AGREEMENTTechnology Transfer Agreement • May 23rd, 2018 • Realm Therapeutics PLC • Pharmaceutical preparations • Pennsylvania
This Technology Transfer Agreement (“Agreement”) is entered into as of April 4, 2018 (“Effective Date”) between Realm Therapeutics, Inc., a Delaware corporation (“RTI”) and Vitold M. Bakhir (“Licensor”) and sets forth the terms and conditions that will apply to the transfer of certain technology and the grant of certain licenses from Licensor to RTI.
MASTER SERVICES AGREEMENT AND EXCLUSIVE PATENT LICENSEMaster Services Agreement and Exclusive Patent License • May 23rd, 2018 • Realm Therapeutics PLC • Pharmaceutical preparations • Delaware
This Master Services Agreement and Exclusive Patent License (“Agreement”), effective as of October 1, (the “Effective Date”) is made by and between PuriCore, Inc. a Delaware Corporation with offices at 508 Lapp Road, Malvern, PA 19355 (hereinafter referred to as “PuriCore”) and Vitold Mikhailovich Bakhir, an individual located at [*] (hereinafter referred to as “Inventor”). PuriCore and Inventor are each referred to herein as a “Party” and collectively as the “Parties.”
DATED , 2017Warrant Instrument • May 23rd, 2018 • Realm Therapeutics PLC • Pharmaceutical preparations • London
This warrant instrument (this “Warrant Instrument”) has been entered into by the Company by way of deed poll relating to the Warrants to subscribe for the Warrant Shares (as such terms are defined herein), subject to the Company's articles of association.
NPLUS1 SINGER ADVISORY LLPRelationship Agreement • May 23rd, 2018 • Realm Therapeutics PLC • Pharmaceutical preparations
ASSET PURCHASE AGREEMENT by and between CHEMSTAR CORP., (a Florida corporation) PURICORE, INC. (a Delaware corporation) andAsset Purchase Agreement • May 23rd, 2018 • Realm Therapeutics PLC • Pharmaceutical preparations • Delaware
This ASSET PURCHASE AGREEMENT is made as of September 19, 2016 by and between PuriCore, Inc., a Delaware corporation (“Seller”), Chemstar Corp., a Florida corporation (“Buyer,” and together with Seller, the “Parties”), and, solely for purposes of Sections 4, 6.1, 8.7, 8.8, 8.11, 10 and 11 hereof, PuriCore plc, a public limited company incorporated under the laws of England and Wales and the parent entity and sole stockholder of Seller (“Parent”).
INTELLECTUAL PROPERTY LICENSE AGREEMENTIntellectual Property License Agreement • May 23rd, 2018 • Realm Therapeutics PLC • Pharmaceutical preparations • Delaware
This Intellectual Property License Agreement (“this Agreement”) is effective as of October 7, 2016 (“Effective Date”), and is made by and between PuriCore, Inc., a Delaware corporation (“LICENSOR”), and Chemstar Corp., a Florida corporation (“LICENSEE”).
